Drug Profile
Ripretinib - Deciphera Pharmaceuticals
Alternative Names: DCC-2618; QINLOCKLatest Information Update: 01 Mar 2024
Price :
$50
*
At a glance
- Originator Deciphera Pharmaceuticals
- Developer Deciphera Pharmaceuticals; Specialised Therapeutics Asia; ZAI Lab
- Class Amines; Antineoplastics; Bromobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Naphthyridines; Phenylurea compounds; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Proto oncogene protein b raf inhibitors; Proto-oncogene protein c-kit expression inhibitors; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Gastrointestinal stromal tumours
- Phase I Solid tumours; Systemic mastocytosis
- No development reported Glioblastoma
Most Recent Events
- 31 Jan 2024 Deciphera Pharmaceuticals has patent protection for ripretinib in Europe, Australia, South America, and Asia
- 18 Jan 2024 Adverse events data from a phase III INTRIGUE trial in Gastrointestinal stromal tumours presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
- 12 Jan 2024 Deciphera Pharmaceuticals enters into a distribution agreement with GENESIS Pharma for ripretinib in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia